Pall — Q1 FY2015 Earnings Presentation
18 slides from Pall's earnings presentation, Nov 25, 2014
Slide 1: Q1 FY 2015 Financial Results
Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2014 Pall Corporation Q1 FY 2015 Financi
Slide 2: Forward-looking statements
2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the first quarter of fiscal year 2015 are preliminary until our Form 10-Q is filed with the Securities and Exchange Commission on or befor
Slide 3: Conference Call Information
3 Conference Call Information Dial-In: Toll-Free 855.356.7268 International 706.634.1981 Replay: Toll-Free 855.859.2056 International 404.537.3406 Conference ID: 29298729 Internet: www.pall.com/investor Pall’s Stax™ Depth Filter System, scalable modules for pre-filtration and clarification i
Slide 4: Q1 Overview
4 Q1 Overview Exceptionally strong quarter – Revenue – Cost control – Cash Flow Solid incremental margins – Business is very leverageable with sufficient revenue growth Translational FX headwinds – Current rates are a significant headwind to our FY15 guidance assumptions Very strong conversion
Slide 5: Q1 Financial Summary
5 $630 $696 $- $200 $400 $600 $800 Revenue % Growth Excluding FX FY 2014 FY 2015 Q1 Financial Summary Dollars in millions, except EPS data A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix. 17.1% 19.2% 10.0% 15.0% 20.0% Operat
Slide 6: Q1 Sales by Segment
6 Life Sciences Consumables $323 +12% Industrial Consumables $282 +13% Industrial Systems $62 +16% Life Sciences Systems $29 +28% 41% 46% 9% 4% Q1 Sales by Segment Dollars in millions Percentages outside pie charts and in box represent sales change excluding FX Percentages inside pie charts represen
Slide 7: Q1 Life Sciences Segment Performance
7 Q1 Life Sciences Segment Performance Dollars in millions Life Sciences markets’ consumables sales growth percentages are excluding FX A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix 0% 30% 60% 56.3% -80 bps 57.1% 0% 30% 60
Slide 8: Q1 Industrial Segment Performance
8 Q1 Industrial Segment Performance Gross Margin Segment Margin Process Technologies consumables: +19% Aerospace consumables: +6% Microelectronics consumables: +8% 0% 30% 60% 47.3% +110 bps 46.2% 0% 30% 60% 18.7% +250 bps 16.2% FY 2014 FY 2015 Sales Q1 FY 2015 YoY Change YoY Change Excluding F
Slide 9: Cash Flow and Working Capital
9 Cash Flow and Working Capital(1) Operating Cash Flow 115$ 86$ CapEx (10) (19) Free Cash Flow 104$ 67$ Other Significant Sources/(Uses) of Cash: Dividends (30) (28) Notes Payable 300 90 Share Repurchase (300) (125) YTD FY15 YTD FY14 Dollars in millions (1) Figures include the impact of rounding Net
Slide 10: Media Technology Enhances Our Position
10 Media Technology Enhances Our Position “Taking share while building the moat” Ultimate Barriers Competition Pall Position Product Channel Applications Regulatory Novel Filter Formats/ IP Media IP Excellence in Supply
Slide 11: FX Update
11 1.50 1.55 1.60 1.65 1.70 1.75 Aug-13 Oct-13 Jan-14 Apr-14 Jul-14 GBP / USD FX Update Recent FX Trends FY14 Revenue by Currency Source: Bloomberg, as of 11/21/2014 Dollars in millions Revenue by functional currency $798 $797 $218 $177 $173 $626 Other 22% RMB 6% GBP 6% JPY 8% USD 29% EUR 29% FY15 F
Slide 12: FY 2015 Revised Outlook
12 FY 2015 Revised Outlook Previous (8/28/14) Updated (11/25/14) Pall Revenue Growth: Total: Organic ex-Fx: Mid-to-high single-digit Low-to-mid single-digit Low to mid single-digit Mid single-digit Segment Revenue Growth: Life Sciences ex-Fx: Industrial ex-Fx: Mid-to-high single-digit Mi
Slide 13: Appendix
Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2014 Pall Corporation Appendix
Slide 14: Appendix: Q1 Earnings and FY 2015 Estimates Reconciliation
14 Appendix: Q1 Earnings and FY 2015 Estimates Reconciliation of Non-GAAP Financial Measures Diluted EPS as reported 0.81$ 0.63$ 3.77$ Discrete Items: ROTC after pro forma tax effect 0.08 0.07 0.08 Total discrete items 0.08 0.07 0.08 Pro forma diluted EPS 0.89$ 0.70$ 3.85$ FY 2015 (Estimates at Midp
Slide 15: Appendix: Q1 Sales By Market & Technology Reconciliation
15 Appendix: Q1 Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q1 FY15 Q1 FY15 Estimated Impact of FX Q1 FY15 Estimate Excluding FX Q1 FY14 % Change Excluding FX Life Sciences Consumables Sales: BioPharmaceuticals 226,605$ (5,625)$ 232,230$ 196,118$ 18.4% Food & Beverage
Slide 16: Appendix: Q1 Orders by Segment Reconciliation
16 Appendix: Q1 Orders by Segment Reconciliation of Non-GAAP Financial Measures Dollars in thousands Q1 FY15 Q1 FY15 Estimated Impact of FX Q1 FY15 Estimate Excluding FX Q1 FY14 % Change Excluding FX Life Sciences Orders: Consumables 337,471$ (9,499)$ 346,970$ 299,140$ 16.0% Systems 30,869 (1,240) 3
Slide 17: Appendix: Q1 Organic Sales Growth by Segment Reconciliation
17 Appendix: Q1 Organic Sales Growth by Segment Reconciliation of Non-GAAP Financial Measures Q1 FY15 Q1 FY14 Percent Change Q1 FY15 Impact of FX % Change Excluding FX Life Sciences Sales: Organic 339,322$ 318,946$ 6.4% (9,757)$ 9.4% Acquisitions 13,142 - - Total Life Sciences Sales 352,464$ 318,946
Slide 18: Appendix: Q1 Operating Profit Reconciliation
18 Appendix: Q1 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q1 FY15 Q1 FY14 Life Sciences segment profit 86,480$ 73,045$ Industrial segment profit 64,232 50,482 Total segment profit 150,712$ 123,527$ General corporate expenses (16,737) (15,964) Operating profit 13